Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France on volume and cost of drug deliveries, assessed with administrative databases.

MLA

Mari, K., et al. “Impact of Terminating Reimbursement of Symptomatic Slow-Acting Drugs in Osteoarthritis in France on Volume and Cost of Drug Deliveries, Assessed with Administrative Databases.” Seminars in Arthritis & Rheumatism, vol. 50, no. 6, Dec. 2020, pp. 1307–13. EBSCOhost, https://doi.org/10.1016/j.semarthrit.2020.09.001.

APA

Mari, K., Rannou, F., Guillemin, F., Elegbede, M., Gueyffier, F., Badot, G., & Mistretta, F. (2020). Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France on volume and cost of drug deliveries, assessed with administrative databases. Seminars in Arthritis & Rheumatism, 50(6), 1307–1313. https://doi.org/10.1016/j.semarthrit.2020.09.001

Chicago

Mari, K., F. Rannou, F. Guillemin, M. Elegbede, F. Gueyffier, G. Badot, and F. Mistretta. 2020. “Impact of Terminating Reimbursement of Symptomatic Slow-Acting Drugs in Osteoarthritis in France on Volume and Cost of Drug Deliveries, Assessed with Administrative Databases.” Seminars in Arthritis & Rheumatism 50 (6): 1307–13. doi:10.1016/j.semarthrit.2020.09.001.